Question

A new drug for asthma has been licensed for marketing in Australia. It has a novel mechansim of action. In the intial stages of its marketing, it is MOST likely to be sold as a schedule __ drug to allow control of its use and monitoring of possible adverse effects.

A) Schedule 1

B) Schedule 2

C) Schedule 3

D) Schedule 4

Answer 1

The new asthma drug with a novel mechanism of action is likely to be sold as a schedule 3 drug in Australia during its initial stages of marketing, allowing for control of its use and monitoring of adverse effects.

Step-by-step explanation:

In the initial stages of its marketing, the new drug for asthma with a novel mechanism of action is MOST likely to be sold as a schedule 3 drug in Australia. This classification would allow for control of its use and monitoring of possible adverse effects. Schedule 3 drugs are available without a prescription but are kept behind the counter and may require consultation with the pharmacist. They are considered to have a moderate potential for abuse or misuse.